Filing Details

Accession Number:
0000313143-13-000165
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-17 18:25:15
Reporting Period:
2013-09-13
Filing Date:
2013-09-17
Accepted Time:
2013-09-17 18:25:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
313143 Haemonetics Corp HAE Surgical & Medical Instruments & Apparatus (3841) 042882273
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1497881 P Michael Kelly 400 Wood Road
Braintree MA 02184
President, Global Markets No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-09-13 1,400 $27.49 12,737 No 4 M Direct
Common Stock Disposition 2013-09-13 1,400 $40.36 11,337 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2013-09-13 1,400 $40.36 1,400 $27.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
51,340 2011-07-28 2017-07-28 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Non-Qualified Stock Option (right to buy) $30.67 2012-10-25 2018-10-25 37,326 37,326 Direct
Common Stock Non-Qualified Stock Option (right to buy) $39.06 2013-10-24 2019-10-24 39,344 39,344 Direct
Common Stock Performance Shares $0.00 2027-03-31 2017-12-31 25,000 25,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2018-10-25 37,326 37,326 Direct
2019-10-24 39,344 39,344 Direct
2017-12-31 25,000 25,000 Direct
Footnotes
  1. Pursuant to a 10b5-1 Plan.
  2. Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
  3. Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).